SCHEMBL5896124

SCHEMBL5896124

O=Cc1cccc(Oc2ccccc2Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 3/20 0.49
LMNA P02545 3/20 0.49
MEN1 O00255 1/20 0.49
MAOA P21397 6/20 0.47
MAOB P27338 6/20 0.47
HPGD P15428 2/20 0.47
GAA P10253 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TTR P02766 2/20 0.46
SRC P12931 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
DPP4 P27487 1/20 0.42
AR P10275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30458091 1.00 MAPT (0.49) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL4938844 0.82 MAPT (0.47) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL19243059 0.81 MAOA (0.50) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL8546960 0.81 TTR (0.53) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL2317083 0.81 ALDH1A1 (0.49) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL30758635 0.81 ALDH1A1 (0.49) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL11224876 0.80 TTR (0.56) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL4294454 0.80 ALDH1A1 (0.49) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL4233381 0.80 TTR (0.50) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL2075852 0.80 TTR (0.67) MAPTKMT2AALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2025-08-21 US disclosed
US-12318383-B2 Dual MAGL and FAAH inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2025-06-03 US disclosed
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 EP disclosed
EP-3615515-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2024-09-25 EP disclosed
EP-4424683-A2 DUAL MAGL AND FAAH INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2024-09-04 EP disclosed
EP-3595665-B1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER INC (US) 2024-08-28 EP disclosed
CN-118271288-A Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2024-07-02 CN disclosed
CN-117736178-A Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2024-03-22 CN disclosed
EP-4335848-A2 DUAL MAGL AND FAAH INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2024-03-13 EP disclosed
CN-117510468-A Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2024-02-06 CN disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed
WO-2003037271-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS,INC. (US) 2003-05-08 WO disclosed
EP-0746323-A4 1997-01-22 EP disclosed
EP-0746323-A1 INHIBITORS OF PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C MERCK & CO. INC. (US) 1996-12-11 EP disclosed
WO-1995010286-A1 INHIBITORS OF PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C MERCK & CO., INC. (US) 1995-04-20 WO disclosed
EP-0003427-B1 PREPARATION OF M-(P-BROMOPHENOXY)BENZALDEHYDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-10-14 EP disclosed
US-4212829-A Preparation of m-(p-bromophenoxy)benzaldehyde SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-07-15 US disclosed
EP-0003427-A1 Preparation of m-(p-bromophenoxy)benzaldehyde SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 MAPT 3583/4885KMT2A 2798/4885ALDH1A1 832/4885
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS FAAH, FAAH2, MAG MAPT 812/4885KMT2A 2187/4885ALDH1A1 1891/4885
US-12318383-B2 Dual MAGL and FAAH inhibitors FAAH, FAAH2, MAG MAPT 812/4885KMT2A 2187/4885ALDH1A1 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.